Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Second-Line Sequencing May Hinge on IHC Staining in Cervical Cancer

April 7th 2025

IHC staining is top of mind for the use of ADCs in cervical cancer management; however, the specific indications for each agent must be considered.

ctDNA-Guided Approaches Reveal Effective Adjuvant Agents in MRD+ CRC

April 7th 2025

Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.

IO Research Pays Off in MSI-H/dMMR CRC but Misses the Mark in MSS/pMMR Disease

April 6th 2025

Tanios S. Bekaii-Saab, MD, discusses questions that have arisen regarding the use of immunotherapy in patients with MSI-H/dMMR and MSS/pMMR CRC.

Second- and Third-Generation TKI Combo Therapies Are at the Forefront of Frontline Ph+ ALL Investigations

March 28th 2025

Gregory Roloff, MD, highlights ongoing frontline TKI research in Ph-positive ALL and why he uses a newer-generation TKI over imatinib.

Blinatumomab Consolidation Prevents B-ALL Relapses and CAR T-Cell Therapy Consolidation May, Too

March 26th 2025

Gregory Roloff, MD, details data on consolidation therapy with blinatumomab or CAR T-cell therapy for B-ALL, and the role of these agents in this setting.

Oncolytic Adenovirus TILT-123 Plus Pembrolizumab Is Tolerable in Platinum-Resistant/Refractory Ovarian Cancer

March 26th 2025

TILT-123 plus pembrolizumab was active in platinum-resistant/refractory ovarian cancer in the phase 1a PROTA trial and the phase 1b portion is ongoing.

Mirvetuximab Soravtansine Stakes Claim as SOC in FRα+ Platinum-Resistant Ovarian Cancer

March 26th 2025

Toon Van Gorp, MD, PhD, discusses the final analysis of the phase 3 MIRASOL trial of mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer.

KRAS G12C and Beyond: KRAS Targeted Agents of Interest Under Development in NSCLC

March 25th 2025

Benjamin Herzberg, MD, highlights novel therapies in the KRAS-mutated NSCLC landscape and ongoing questions research is seeking to answer in this space.

Nivolumab Plus Sunitinib Hits Primary End Point in Advanced Bone Sarcoma IMMUNOSARC Study

March 25th 2025

Nivolumab plus sunitinib displayed early-phase efficacy in advanced bone sarcoma.

Divarasib Looks to Best Sotorasib/Adagrasib and Solidify a Role in KRAS G12C-Mutated NSCLC

March 24th 2025

Benjamin Herzberg, MD, details research in KRAS G12C-mutated NSCLC with divarasib and how he currently selects between available therapies in this space.

Improving Outcomes for Patients With Anal Cancer By Raising Awareness

March 21st 2025

For Anal Cancer Awareness Day, Sheela Rao, MBBS, MD, FRCP, discusses present and upcoming treatment strategies, unmet needs, and the future of the field.

First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC

March 21st 2025

Real-world data showed that atezolizumab provided a benefit and was safe in patients with platinum-ineligible mUC and high comorbidities/functional status.

IL-Agonist NKTR-255 Shows Ability to Enhance Responses to CAR T-Cell Therapy in R/R LBCL

March 20th 2025

Sairah Ahmed, MD, discusses findings from a phase 2 trial of NKTR-255 after CD19-directed CAR T-cell therapy in relapsed/refractory LBCL.

PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC

March 20th 2025

Monica Chatwal, MD, details new research shedding light on PARP/ARPI combinations in mCRPC, especially in BRCA-mutated and HRR gene–altered populations.

HER2DX Affects Approximately 50% of Treatment Decisions for HER2+ Breast Cancer

March 18th 2025

HER2DX aided in HER2+ breast cancer therapy decisions and the pCR rate was comparable among those who did and did not have HER2DX-driven treatment changes.

Nadofaragene Firadenovec Is Effective With Beneficial Dosing Schedule in Real-World for BCG-Unresponsive NMIBC

March 18th 2025

Mark Tyson II, MD, MPH, and Jacob Moyer, BS, detail findings from the first real-world study of nadofaragene firadenovec in BCG-unresponsive NMIBC.

Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma

March 18th 2025

P-BCMA-ALLO1 displayed high response rates and compelling safety in a heavily pretreated population of patients with relapsed/refractory multiple myeloma.

Pembrolizumab Plus Lenvatinib Elicits Clinically Meaningful Responses in Platinum-Resistant HGSOC

March 17th 2025

The combination of pembrolizumab and lenvatinib showed promising activity including durable responses in patients with platinum-resistant HGSOC.

Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer

March 15th 2025

Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.

Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer

March 15th 2025

Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.